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The successful use of the co-formulation of Tenofovir
(TDF) and Emtricitabine (FTC) to prevent HIV infection
among gay men was successfully demonstrated in 2010 in
the iPREX trial. Moreover, this randomized placebo-con-
trolled study showed that men who were adherent in
regard to the once-daily use of TDF/FTC were at low risk
for acquisition of HIV in comparison to both non-treated
controls and men who were not as adherent to their
recommended drug intake (44% protection overall but
92% protection among adherent populations). Similar
findings were obtained in a different study termed Part-
ners/Prep performed in two developing countries. Yet,
despite these positive results, the idea of PrEP remains
controversial in some settings, and the following concerns
among others have been expressed.
1. The use of antiretroviral drugs in PrEP may deprive
some people already infected by HIV of the chance to
benefit from these same drugs, due to competition for
resources and/or drug supply.
2. The use of PrEP will promote sexual promiscuity
and lead to more STDs.
3. Although PrEP has worked in controlled trials, it
will be less likely to be successful in real world settings,
where adherence and counselling may be less than
adequate,
4. PrEP may promote HIV drug resistance in real
world settings if ARVs are taken by people who may
already be HIV-infected and don´t know it.
5. Not all PrEP trials have been successful, e.g. VOICE
and FEM-PrEP.
6. The daily consumption of ARVs may be toxic.
One potential solution to some of these concerns may
be the use of PrEP on an intermittent basis, in which
ARVs are taken only on the day of anticipated sexual
relations and for two days after a sexual encounter. This
concept could have the advantage of lowering both
costs and drug-related toxicities.
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